Genentech-Lodo sign agreement for soil-based drug discovery
Category: #health  By Paroma Bhattacharya  Date: 2018-05-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech-Lodo sign agreement for soil-based drug discovery

Genentech, a Roche subsidiary, has reportedly signed a deal with Lodo Therapeutics for around $1 billion to employ the genome mining technology of Lodo for a new drug discovery. The deal seems to be a first for Lodo which has a backing of $17 million from Accelerator Life Science Partners.

If reports are to be believed, the alliance includes an upfront amount that has not been disclosed and commercial and research and development milestone payments of $969 million. In the event that the products reach the market, tiered royalties would be provided on sales, as per a clause included in the deal. The disease categories that will be pursued through the alliance have not yet been disclosed.

Sources state that natural products have been the starting point for various drugs – similar to how microorganisms and plants have been the origins of various drugs like aspirin, derived from willow bark. As per estimates, in the last few decades, around three quarters of cancer drugs and medicines to treat chronic diseases like type 2 diabetes have been derived from natural sources. Authentic reports suggest that the increased focus of pharmaceutical companies on large-molecule drugs and synthetic small-molecules drugs based on combinatorial chemistry has slowed down the investment in naturally sourced drugs. However, this collaboration seemingly points toward the renewal of interest in naturally sourced medicines.

In partnership with Genentech, Lodo will search for naturally-occurring small molecules from microbial DNA that exhibit therapeutic potential. The process of drug discovery can be slow and depends largely on chance. Lodo Therapeutics claims to be able to speed up the process with its genome-based approach that also helps in lowering the costs of finding compounds for drug resistant bacterial infections and cancer.

Reliable sources quoted co-founder of Lodo Therapeutics, David Pompliano, saying that the strategic collaboration of Lodo Therapeutics with one of the leaders of innovative drug technology clearly highlights the potential of the proprietary platform that Lodo represents and its value to advanced drug discovery initiatives.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

PhaseBio reveals Phase 2a study results for PB2452 in older patients
PhaseBio reveals Phase 2a study results for PB2452 in older patients
By Paroma Bhattacharya

The new data is consistent with the formally published Phase 1 trial data of younger subjects treated with ticagrelor alone

PhaseBio Pharmaceutical Inc., a clinical...

Silk Road unveils results from ROADSTER-2 study of transcarotid stent
Silk Road unveils results from ROADSTER-2 study of transcarotid stent
By Paroma Bhattacharya

Silk Road Medical, Inc., a medical device company focused on reducing the risk of stroke and its harmful impact, has recently announced positive final results for its ROADSTER-2 post-marketing study which evaluated the...

Target Corporation announces expansion of same-day shipping option
Target Corporation announces expansion of same-day shipping option
By Paroma Bhattacharya

Customers will be able to pay with their Target credit cards, which offer them a discount of 5 percent.

Target Corporation has reportedly announced that it will st...